New triple therapy aims to tame melanoma treatment's worst side effects
NCT ID NCT03999749
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding tocilizumab to standard immunotherapy (ipilimumab + nivolumab) can reduce severe immune-related side effects in people with advanced melanoma that cannot be removed by surgery. About 71 participants will receive the three-drug combination during an induction phase, followed by maintenance nivolumab alone for up to one year. The main goals are to measure safety and tumor response.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
NYU Langone Health
New York, New York, 10016, United States
-
The Angeles Clinic
Los Angeles, California, 90025, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can new drug cocktails reawaken the immune system against melanoma?
- Could a Six-Month exercise and diet plan shield muscle during melanoma treatment?
- Quitting before the knife: which Stop-Smoking aid works best for cancer patients?
- Can a One-Two punch of immune boosters revive cancer treatment?
- Can a modified herpes virus turn the tide against advanced cancer?
- Can your genes predict your melanoma risk?